Novavax, Inc. Initiates Phase 1 Clinical Trial of RSV Vaccine Candidate in Elderly Adults

Published: Oct 16, 2012

ROCKVILLE, Md., Oct. 15, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 1 dose-ranging clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adults 60 years of age and older.

Back to news